There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
To report the rates of grade IV adverse events and hepatitis C virus (HCV) treatment
discontinuation associated with the use of telaprevir, pegylated interferon, and ribavirin.
[1
]
aDepartment of Medicine, Owen Clinic bDivision of Infectious Diseases, Department
of Medicine cSkaggs School of Pharmacy and Pharmaceutical Sciences, University of
California at San Diego, San Diego, California, USA.